Repligen (NASDAQ:RGEN) Issues Quarterly Earnings Results, Meets Estimates

Repligen (NASDAQ:RGEN) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33, Briefing.com reports. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter in the prior year, the firm posted $0.53 EPS. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Repligen updated its FY24 guidance to $1.42-1.49 EPS and its FY 2024 guidance to 1.420-1.490 EPS.

Repligen Stock Up 1.3 %

RGEN traded up $2.01 during trading on Wednesday, reaching $162.60. 38,544 shares of the stock were exchanged, compared to its average volume of 624,833. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13. The stock has a market cap of $9.09 billion, a P/E ratio of 642.39, a price-to-earnings-growth ratio of 4.62 and a beta of 0.95. The stock’s 50 day moving average price is $134.67 and its two-hundred day moving average price is $166.12. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35.

Insider Buying and Selling at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Martin D. Madaus acquired 1,615 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the topic of several analyst reports. JPMorgan Chase & Co. lowered their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Guggenheim started coverage on shares of Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating for the company. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and lowered their price target for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.